Abstract |
A fluorinated 2-nitroimidazole radiosensitizer KU-2285 was given before intraoperative radiotherapy (IORT) to 30 patients with unresectable, unresected or macroscopic residual tumours. Twenty-three patients had pancreatic cancer and five had osteosarcoma. The IORT dose was 30 Gy for unresectable pancreatic cancer and 60 Gy for osteosarcoma. The dose of KU-2285 administered ranged from 1 to 9 g m-2. Four patients received a dose of 9 g m-2, and ten received 6.8-7 g m-2. All patients tolerated KU-2285 well, and no drug-related toxicity was observed. The average tumour concentration of KU-2285 immediately after IORT was 166 microg g-1 at dose of 6.8-7 g m-2 and 333 microg g-1 at 9 g m-2. The average tumour-plasma ratio was > or = 0.82. Eleven patients with unresectable but localized pancreatic cancer treated with KU-2285 plus IORT and external beam radiotherapy had a median survival time of 11 months and 1-year local control rate of 50%, which compares favourably with those of 8 months (P = 0.26) and 28% (P = 0.10) for 22 matched historical control patients. The five patients with osteosarcoma attained local control. The results of this first study on KU-2285 and IORT appear encouraging, and further studies of this compound seem to be warranted.
|
Authors | Y Shibamoto, G Ohshio, R Hosotani, Y Nishimura, T Manabe, M Imamura, M Abe |
Journal | British journal of cancer
(Br J Cancer)
Vol. 76
Issue 11
Pg. 1474-9
( 1997)
ISSN: 0007-0920 [Print] England |
PMID | 9400944
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Nitroimidazoles
- Radiation-Sensitizing Agents
- KU 2285
|
Topics |
- Adolescent
- Adult
- Aged
- Bone Neoplasms
(radiotherapy, surgery)
- Child
- Combined Modality Therapy
- Female
- Humans
- Intraoperative Care
- Male
- Middle Aged
- Nitroimidazoles
(adverse effects, pharmacokinetics, therapeutic use)
- Osteosarcoma
(radiotherapy, surgery)
- Pancreatic Neoplasms
(radiotherapy, surgery)
- Radiation-Sensitizing Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Treatment Outcome
|